HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer

Dr Bartlett talks to ecancertv at SABCS 2015 about using HER2 status as a predictive marker for benefiting from treatment with an aromatase inhibitor (AI) versus tamoxifen based on data from a meta-analysis of more than 12,000 patients who participated…

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1ZqIPW1
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1NDTKX3
via IFTTT